|drug959||Daily Vitamin D3 Wiki||1.00|
|D014808||Vitamin D Deficiency NIH||0.32|
|D014777||Virus Diseases NIH||0.11|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The purpose of this study is to evaluate how useful vitamin D supplementation is in reducing the severity of COVID-19 symptoms and the body's inflammatory and infection-fighting response to COVID-19. Individuals ≥50 years of age and older who are tested for COVID-19 and negative will be randomized (like flipping a coin) to either daily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care. Those individuals ≥50 years of age or older who test positive for COVID-19 at baseline will be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose (6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receive a multivitamin containing vitamin D.
Description: metabolite of vitamin DMeasure: Change in total circulating 25(OH)D concentration Time: monthly in COVID-19 negative participants through study completion for 1 year
Description: metabolite of vitamin DMeasure: Change in total circulating 25(OH)D concentration in COVID-19 positives Time: baseline, 2 and 4 weeks, then months 3, 6, 9 and 12 in COVID-19 positive participants
Description: The presence or absent of SARS-CoV-2 antibody will be measured at baseline, 3, 6, 9 and 12 months.Measure: Change in SARS-CoV-2 antibody titers Time: every 3 months up to 12 months
Description: At baseline, 3, 6, 9 and 12 months, inflammatory cytokines will be measured in participant plasma samples. Cytokines to be measured are Interferon-gamma (IFN-g), Interleukin-1beta (IL-1B), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, and Tumor Necrosis Factor-alpha (TNFa). Values of these cytokines at baseline will compared to those at 3, 6, 9, and 12 monthsMeasure: Change in inflammatory cytokine concentration (10 cytokine panel Elisa: Interferon (INF)-gamma, Interleukin (IL)-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-13, Tumor Necrosis Factor (TNF)-alpha Time: baseline and every 3 months up to 12 months
Description: COVID-19 positive participants or if COVID-19 negatives develop respiratory symptoms will complete this respiratory survey daily for 2 weeksMeasure: Respiratory symptoms Time: daily for 2 weeks
Description: Inventory of signs and symptoms of rhino/sinusitis. These signs include sneezing, running nose, cough, dizziness, fatigue, and sense of smell. Each sign is rated on a scale of 0 to 5, with 0 indicating not problem, for instance 1 indicating mild problem, 4 indicating severe problem and 5 indicating problem as bad as it can be.Measure: Signs and symptoms of rhino/sinusitis Time: Baseline then 3, 6, 9 and 12 months in negatives and daily for 2 weeks in positives
Description: Dietary intake assessmentMeasure: NCI Dietary Intake Time: baseline then at 6 and 12 months
Description: Survey of participant health problemsMeasure: Charlson Comorbidity survey Time: baseline then at 6 and 12 months
Description: Assessment of physical activity of each participantMeasure: Paffenberger Physical Activity Assessment Time: Baseline then at 6 and 12 months
Description: Each participant will complete the Perceived Stress Scale Questionnaire (PSS) to assess their perceived stress. Assessments are base on a scale of 0 to 4, with 0 indicating "never" and 4 indicating "very often"Measure: Perceived stress Time: monthly for 1 year
Description: Each participant will complete the and Pandemic Stress Index Questionnaire (PSI) to assess their perceived stress cause by the pandemic. Assessments are base on a scale of 0 to 6, with 0 indicating "not at all" and 5 indicating "extremely," and 6 indicating "decline to answer."Measure: Pandemic stress Time: monthly for 1 year
Description: Personality characteristics of each participantMeasure: NEO-Personality Inventory Time: baseline visit
Description: A health assessment will be completed by each participant monthly for 1year. This health. This is for information on health status only and not for comparative assessment.Measure: GrassrootsHealth Monthly Health assessment Time: baseline, 6, and 12 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports